In a phase II randomized clinical trial of ADI-PEG20 on mesothelioma patients, ADI-PEG20 improved PFS in patients with ASS1-deficient mesothelioma and the adverse effects observed in patients were tolerable [139]. The gene discussed is ASS1; the disease is mesothelioma.